 "Shasun Pharmaceuticals gains on USFDA nod for Carisoprodol tablets")
Shares of Shasun Pharmaceuticals were up nearly 2% at Rs 405 after the company said it has received an approval from the US Food and Drug Administration for Carisoprodol tables USP in dosages from 250mg and 350mg.
Carisoprodol tablets in the aforesaid dosages has sales of approximately $38 million. While the dosage of 350mg has few generic players, Shasun expects to be the first marketed generic player in the $16 million Carisoprodol tablets 250mg opportunity, the company said in a release.
The product will be manufactured at the Pondicherry facility of the company and distributed in US through a partner. The product is expected to be launched shortly, the release added.
The stock opened at Rs 398 and touched a high of Rs 408. At 12:30pm, over 176,000 shares were traded on both the stock exchanges.
